Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltext